SBIR Phase I: Early Diagnosis of the COVID-19 Cytokine Storm via Point-of-Care Antibody Profiling

SBIR 第一阶段：通过护理点抗体分析对 COVID-19 细胞因子风暴进行早期诊断

• 批准号: 2036098
• 负责人: Anna Schibel
• 金额: $ 25.6万
• 依托单位: Electronic Bio Sciences
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2036098&HistoricalAwards=false
• 关键词: SBIR; Phase; Early; Diagnosis; COVID

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to predict a patient’s risk for developing an adverse and often lethal response to certain viral infections, such as COVID-19. This project proposes a fast and accurate test for the severity of COVID-19 infection. The proposed assay has the potential to enable early intervention and save lives. It can potentially be used for many other infections and public health hazards beyond COVID-19.This Small Business Innovation Research (SBIR) Phase I project will produce a new technology capable of diagnosing immune response dysregulation to any infectious disease (e.g., SARS-CoV-2, dengue, influenza, hepatitis C, etc.) that progress through an antibody dependent enhancement (ADE) mechanism. While infection by the SARS-CoV-2 virus begins as a mild illness, some patients experience a sudden and rapid decline in health, precipitated by a massive release of pro-inflammatory cytokines, i.e., a “cytokine storm,” Cytokine storms cause hyperinflammation of the lungs, which leads to acute respiratory distress syndrome (ARDS), the leading cause of COVID-19 mortality. Unfortunately, there is presently no test capable of predicting this event. This project aims to fill this medical technology gap via the development of a highly multiplexed, rapid, sensitive, disposable immunoassay specific to COVID-19 infections to be deployed at scale. The effort will include designing, building, and optimizing a prototype immunoassay based on nanopore technology innovations and analytically validating the developed technology against industry standards.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛的影响/商业潜力是预测患者对某些病毒感染（例如Covid-19）产生不良反应和致命反应的风险。该项目提出了对Covid-19感染严重程度的快速准确测试。拟议的评估有可能提早干预并挽救生命。它可能用于许多其他感染和共同危害COVID-199的其他感染和公共卫生危害。这项小型企业创新研究（SBIR）I阶段项目将生产一种能够诊断出对任何感染性疾病的诊断免疫反应失调的新技术（例如，SARS-COV-2，SARS-COV-2，SARS-COV-2，DENGUE，DENGUE，DENGUE，DENGUE，DENGE，影响，影响，乙型肝炎等），其通过抗体依赖性依赖于依赖性的机制（ADEDENTENT机制）。 While infection by the SARS-CoV-2 virus begins as a mild illness, some patients experience a sudden and rapid decline in health, precision by a massive release of pro-inflammatory cytokines, i.e., a “cytokine storm,” Cytokine storms cause hyperinflammation of the lungs, which leads to acute respiratory distress syndrome (ARDS), the leading cause of COVID-19 mortality.不幸的是，目前没有能够预测此事件的测试。该项目旨在通过开发高度多路复用，快速，敏感，一次性的免疫测定法，以大规模部署Covid-19感染。这项工作将包括设计，构建和优化基于纳米孔技术创新的原型免疫测定法，并根据行业标准对开发的技术进行分析验证。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子优点和更广泛影响的审查标准来评估通过评估来获得的支持。